Login
Navigate Fool.com
Will IPXL beat
the market?
Community Rating: 3 Stars: Appealing

23.92 -0.39 (-1.60%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $24.26
Previous Close $24.31
Daily Range $23.61 - $25.12
52-Week Range $15.99 - $28.50
Market Cap $1.7B
P/E Ratio 16.27
Dividend (Yield) $0.00 (0.0%)
Volume 976,448
Average Daily Volume 660,303
Current FY EPS $0.73

How do you think IPXL
will perform against the market?

Top IPXL Bull/Bear Pitches

 

SaintCroix (< 20)
Submitted January 16, 2011

The numbers are kinda insane. market cap $1.43 billion p/e 5 PEG 0.72 profit margin 28% operating margin 47% ROE 83% cash $358 million no debt revenue 2008: $210 million revenue 2009: $358 million … More

3 Replies Reply Report this Post
 

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary

Impax Breathes New Life Into Stalled Parkinson's Drug

Impax's (IPXL) stumbles in bringing Rytary, it's long lasting Parkinson's drug, to market may finally be over given its re-filed with the FDA for approval.

Sector Update: Healthcare Shares Lower in Pre-Market Trade

Sector Update: Healthcare

Will Teva Pharmaceuticals Overcome Its Patent Cliff Worries?

Teva's expected loss of patent protection on its blockbuster drug Copaxone in 2014 could further hurt the company's already weak drug sales.

Is Teva's Situation Really So Dire?

Despite Teva’s poor performance recently, it still has several strong points that could revive its stock. How is Teva measuring up to Pfizer and Impax Laboratories?

The Clinical Lowdown: Keryx and Zerenex

A second opinion on the recent Keryx rush.

3 Pipeline Drugs That Could Have a Dramatic Impact on Parkinson's Disease by 2020

Parkinson's disease affects roughly 1 million people in the U.S. but has no cure. Here are three biopharmaceutical companies with promising drugs that are looking to dramatically improve patient quality of life before the decade is over.

Healthcare Stocks Still Rising Near Close; Dynavax Tech Adds 2% After Starting Asthma Drug Study

Sector Update: Healthcare

Trade the Earnings: Impax Laboratories, Inc.

See More IPXL News...

Sector

Healthcare

Industry

Drugs

Impax Laboratories Inc. (IPXL) Description

Impax Laboratories Inc. is a technology-based specialty pharmaceutical company focused on the development and commercialization of bioequivalent and brand-name pharmaceuticals utilizing its controlled-release and other in-house development. Website: http://www.impaxlabs.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks